Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Status:
Suspended
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation
Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who
progress on this antibody. Patients with metastatic melanoma will be enrolled after they have
progressed on anti-PD-1 therapy. Patients with metastatic NSCLC (previously untreated with
anti-PD-1 or anti-PD-L1 therapy) will be enrolled and treated with MK-3475 until they exhibit
progression of disease. At this point (when patients have demonstrated progression of
disease) a single target lesion will be selected and treated with SBRT, and then MK-3475 will
be restarted and continued until there is further progression of disease. The first phase of
the study is a radiation dose escalation with a constant dose of MK-3475. The second part of
the study includes expansion cohorts of NSCLC and melanoma patients.